The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies

Cellular Microbiology

Volumn 11, Issue 6, 2009, Pages 889-897

  Nguyen, Thi Lien Anh ^a,b   Tumilasci, Vanessa Fonseca ^a,b   Singhroy, Diane ^a,b   Arguello, Meztli ^a   Hiscott, John ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; GELDANAMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; ONCOLYTIC VIRUS; PROTEIN BCL 2 INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL THERAPY; CLINICAL TRIAL; DNA VIRUS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INNATE IMMUNITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MEASLES VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PRIORITY JOURNAL; REOVIRUS; RNA VIRUS; SEMLIKI FOREST ALPHAVIRUS; SHORT SURVEY; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RNA VIRUSES;

RNA VIRUSES;

EID: 65549090518     PISSN: 14625814     EISSN: 14625822     Source Type: Journal    
DOI: 10.1111/j.1462-5822.2009.01317.x     Document Type: Short Survey

References (90)

1. Aghi, M., and Martuza, R.L. (2005) Oncolytic viral therapies - The clinical experience. Oncogene 24: 7802-7816.
2. Balachandran, S., and Barber, G.N. (2000) Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50: 135-138.
3. Balachandran, S., and Barber, G.N. (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5: 51-65.
4. Barber, G.N. (2005) VSV-tumor selective replication and protein translation. Oncogene 24: 7710-7719.
5. Bergmann, M., Romirer, I., Sachet, M., Fleischhacker, R., Garcia-Sastre, A., Palese, P., et ]al. (2001) A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 61: 8188-8193.
6. Bieler, A., Mantwill, K., Dravits, T., Bernshausen, A., Glockzin, G., Kohler-Vargas, N., et al. (2006) Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 17: 55-70.
7. Carey, B.L., Ahmed, M., Puckett, S., and Lyles, D.S. (2008) Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol 82: 12104-12115.
8. Cattaneo, R., Miest, T., Shashkova, E.V., and Barry, M.A. (2008) Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
9. Charo, J., Finkelstein, S.E., Grewal, N., Restifo, N.P., Robbins, P.F., and Rosenberg, S.A. (2005) Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res 65: 2001-2008.
10. Coffey, M.C., Strong, J.E., Forsyth, P.A., and Lee, P.W. (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
11. Davis, J.J., and Fang, B. (2005) Oncolytic virotherapy for cancer treatment: Challenges and solutions. J Gene Med 7: 1380-1389.
12. Dingli, D., Peng, K.W., Harvey, M.E., Greipp, P.R., O'Connor, M.K., Cattaneo, R., et al. (2004) Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646.
13. Elankumaran, S., Rockemann, D., and Samal, S.K. (2006) Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 80: 7522-7534.
14. Fabian, Z., Csatary, C.M., Szeberenyi, J., and Csatary, L.K. (2007) p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 81: 2817-2830.
15. Fielding, A.K. (2005) Measles as a potential oncolytic virus. Rev Med Virol 15: 135-142.
16. Figova, K., Hrabeta, J., and Eckschlager, T. (2006) Reovirus -possible therapy of cancer. Neoplasma 53: 457-462.
17. Fiola, C., Peeters, B., Fournier, P., Arnold, A., Bucur, M., and Schirrmacher, V. (2006) Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence. Int J Cancer 119: 328-338.
18. Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S.S., Yu, J., et al. (2006) Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103: 12873-12878.
19. Harrington, K.J., Melcher, A., Vassaux, G., Pandha, H.S., and Vile, R.G. (2008) Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 10: 362-370.
20. Hirasawa, K., Nishikawa, S.G., Norman, K.L., Coffey, M.C., Thompson, B.G., Yoon, C.S., et al. (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353.
21. Hoti, N., Chowdhury, W., Hsieh, J.T., Sachs, M.D., Lupold, S.E., and Rodriguez, R. (2006) Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 14: 768-778.
22. Iankov, I.D., Blechacz, B., Liu, C., Schmeckpeper, J.D., Tarara, J.E., Federspiel, M.J., et al. (2007) Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 15: 114-122.
23. Janicke, R.U., Sohn, D., and Schulze-Osthoff, K. (2008) The dark side of a tumor suppressor: Anti-apoptotic p53. Cell Death Differ 15: 959-976.
24. Janke, M., Peeters, B., de Leeuw, O., Moorman, R., Arnold, A., Fournier, P., et al. (2007) Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 14: 1639-1649.
25. Janke, M., Peeters, B., Zhao, H., de Leeuw, O., Moorman, R., Arnold, A., et al. (2008) Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 33: 823-832.
26. Katsura, T., Iwai, S., Ota, Y., Shimizu, H., Ikuta, K., and Yura, Y. (2009) The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 16: 237-245.
27. Kim, S., Kang, J., Hu, W., Evers, B.M., and Chung, D.H. (2003) Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer 103: 352-359.
28. Kline, M.P., Rajkumar, S.V., Timm, M.M., Kimlinger, T.K., Haug, J.L., Lust, J.A., et al. (2007) ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21: 1549-1560.
29. Kojima, K., Shimanuki, M., Shikami, M., Samudio, I.J., Ruvolo, V., Corn, P., et al. (2008) The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22: 1728-1736.
30. Kottke, T., Diaz, R.M., Kaluza, K., Pulido, J., Galivo, F., Wongthida, P., et al. (2008) Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 16: 1910-1918.
31. Kottke, T., Thompson, J., Diaz, R.M., Pulido, J., Willmon, C., Coffey, M., et al. (2009) Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 15: 561-569.
32. Krishnamurthy, S., Takimoto, T., Scroggs, R.A., and Portner, A. (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80: 5145-5155.
33. Kumar, S., Gao, L., Yeagy, B., and Reid, T. (2008) Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 10: 371-379.
34. Kutuk, O., and Letai, A. (2008) Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res 68: 7985-7994.
35. Lemay, G., Tumilasci, V., and Hiscott, J. (2007) Uncoating reo: uncovering the steps critical for oncolysis. Mol Ther 15: 1406-1407.
36. Lichty, B.D., Power, A.T., Stojdl, D.F., and Bell, J.C. (2004) Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol Med 10: 210-216.
37. Liu, C., Sarkaria, J.N., Petell, C.A., Paraskevakou, G., Zollman, P.J., Schroeder, M., etal. (2007) Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 13: 7155-7165.
38. Liu, C., Erlichman, C., McDonald, C.J., Ingle, J.N., Zollman, P., Iankov, I., et al. (2008a) Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Ther 15: 1024-1034.
39. Liu, T.C., and Kirn, D. (2008) Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Ther 15: 877-884.
40. Liu, T.C., Castelo-Branco, P., Rabkin, S.D., and Martuza, R.L. (2008b) Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 16: 1041-1047.
41. Maatta, A.M., Liimatainen, T., Wahlfors, T., Wirth, T., Vaha-Koskela, M., Jansson, L., et al. (2007) Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models. Int J Cancer 121: 863-870.
42. Minucci, S., and Pelicci, P.G. (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
43. Moon, D.O., Kim, M.O., Choi, Y.H., Kim, N.D., Chang, J.H., and Kim, G.Y. (2008) Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells. Cancer Lett 264: 316-325.
44. Msaouel, P., Dispenzieri, A., and Galanis, E. (2009) Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11: 43-53.
45. Mumm, J.B., and Oft, M. (2008) Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene 27: 5913-5919.
46. Munguia, A., Ota, T., Miest, T., and Russell, S.J. (2008) Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15: 797-806.
47. Nakamura, T., and Russell, S.J. (2004) Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 4: 1685-1692.
48. Nguyen, T.L., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.S., et al. (2008) Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 105: 14981-14986.
49. Norman, K.L., Hirasawa, K., Yang, A.D., Shields, M.A., and Lee, P.W. (2004) Reovirus oncolysis: The Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101: 11099-11104.
50. Noser, J.A., Mael, A.A., Sakuma, R., Ohmine, S., Marcato, P., Lee, P.W., et al. (2007) The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: Implication for the defective interferon response in cancer cells. Mol Ther 15: 1531-1536.
51. Nusinzon, I., and Horvath, C.M. (2006) Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 26: 3106-3113.
52. Oliere, S., Arguello, M., Mesplede, T., Tumilasci, V., Nakhaei, P., Stojdl, D., et al. (2008) Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 82: 5735-5749.
53. Ong, H.T., Hasegawa, K., Dietz, A.B., Russell, S.J., and Peng, K.W. (2007) Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 14: 324-333.
54. Otsuki, A., Patel, A., Kasai, K., Suzuki, M., Kurozumi, K., Chiocca, E.A., et al. (2008) Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 16: 1546-1555.
55. Porosnicu, M., Mian, A., and Barber, G.N. (2003) The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 63: 8366-8376.
56. Power, A.T., and Bell, J.C. (2007) Cell-based delivery of oncolytic viruses: A new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
57. Power, A.T., and Bell, J.C. (2008) Taming the Trojan horse: Optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 15: 772-779.
58. Power, A.T., Wang, J., Falls, T.J., Paterson, J.M., Parato, K.A., Lichty, B.D., et al. (2007) Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.
59. Prestwich, R.J., Harrington, K.J., Pandha, H.S., Vile, R.G., Melcher, A.A., and Errington, F. (2008) Oncolytic viruses: A novel form of immunotherapy. Expert Rev Anticancer Ther 8: 1581-1588.
60. Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, R.M., et al. (2008a) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
61. Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R.M., et al. (2008b) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269.
62. Qiao, J., Wang, H., Kottke, T., Diaz, R.M., Willmon, C., Hudacek, A., et al. (2008c) Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 15: 604-616.
63. Raykov, Z., and Rommelaere, J. (2008) Potential of tumour cells for delivering oncolytic viruses. Gene Ther 15: 704-710.
64. Rodriguez-Madoz, J.R., Prieto, J., and Smerdou, C. (2005) Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 12: 153-163.
65. Russell, S.J., and Peng, K.W. (2007) Viruses as anticancer drugs. Trends Pharmacol Sci 28: 326-333.
66. Russell, S.J., and Peng, K.W. (2008) The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther 10: 380-386.
67. Sacchi, S., Pozzi, S., Marcheselli, R., Federico, M., Tucci, A., Merli, F., et al. (2007) Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 110: 121-128.
68. Sharif-Askari, E., Nakhaei, P., Oliere, S., Tumilasci, V., Hernandez, E., Wilkinson, P., et al. (2007) Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology 365: 20-33.
69. Shin, E.J., Wanna, G.B., Choi, B., Aguila, D., III, Ebert, O., Genden, E.M., et al. (2007) Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope 117: 210-214.
70. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., et al. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
71. Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
72. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., and Lee, P.W. (1998) The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
73. Tam, C.S., O'Brien, S., Wierda, W., Kantarjian, H., Wen, S., Do, K.A., et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975-980.
74. Thorne, S.H., Hermiston, T., and Kirn, D. (2005) Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 32: 537-548.
75. Trudel, S., Li, Z.H., Rauw, J., Tiedemann, R.E., Wen, X.Y., and Stewart, A.K. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438.
76. Tseng, J.C., Levin, B., Hirano, T., Yee, H., Pampeno, C., and Meruelo, D. (2002) In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 94: 1790-1802.
77. Tseng, J.C., Levin, B., Hurtado, A., Yee, H., Perez de Castro, I., Jimenez, M., et al. (2004) Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22: 70-77.
78. Tumilasci, V.F., Oliere, S., Nguyen, T.L., Shamy, A., Bell, J., and Hiscott, J. (2008) Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol 82: 8487-8499.
79. Ungerechts, G., Springfeld, C., Frenzke, M.E., Lampe, J., Johnston, P.B., Parker, W.B., et al. (2007a) Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 67: 10939-10947.
80. Ungerechts, G., Springfeld, C., Frenzke, M.E., Lampe, J., Parker, W.B., Sorscher, E.J., et al. (2007b) An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15: 1991-1997.
81. Vaha-Koskela, M.J., Kallio, J.P., Jansson, L.C., Heikkila, J.E., Zakhartchenko, V.A., Kallajoki, M.A., et al. (2006) Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 66: 7185-7194.
82. Vaha-Koskela, M.J., Heikkila, J.E., and Hinkkanen, A.E. (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
83. Vanden Berghe, T., Kalai, M., van Loo, G., Declercq, W., and Vandenabeele, P. (2003) Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J Biol Chem 278: 5622-5629.
84. Varghese, S., and Rabkin, S.D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967-978.
85. Vigil, A., Park, M.S., Martinez, O., Chua, M.A., Xiao, S., Cros, J.F., et al. (2007) Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res 67: 8285-8292.
86. Wakimoto, H., Fulci, G., Tyminski, E., and Chiocca, E.A. (2004) Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 11: 214-223.
87. Watanabe, T., Hioki, M., Fujiwara, T., Nishizaki, M., Kagawa, S., Taki, M., et al. (2006) Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312: 256-265.
88. Weiss, J.M., Subleski, J.J., Wigginton, J.M., and Wiltrout, R.H. (2007) Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7: 1705-1721.
89. Yap, T.A., Brunetto, A., Pandha, H., Harrington, K., and Debono, J.S. (2008) Reovirus therapy in cancer: Has the orphan virus found a home? Expert Opin Invest Drugs 17: 1925-1935.
90. Zhao, C., and Wang, E. (2004) Heat shock protein 90 suppresses tumor necrosis factor alpha induced apoptosis by preventing the cleavage of Bid in NIH3T3 fibroblasts. Cell Signal 16: 313-321.